Harvoni (ledipasvir/sofosbuvir) yielded a 96 percent cure rate among people with genotype 1 of hepatitis C virus (HCV), as well as a small number of those with genotype 4. The Phase III, open-label ION-4 study of 12 weeks of Harvoni included 335 participants coinfected with HIV, including those with genotype 1a (75 percent), genotype 1b (23 percent) or genotype 4 (2 percent). Read more here: hepmag.com/articles/Harvoni...